Mo1076 Comparison of Night-Time Acid-Suppressive Efficacies of Different Proton Pump Inhibitors in Helicobacter pylori-Negative CYP2C19 Homozygous Extensive Metabolizers: Effect of Rabeprazole at High and Twice Daily Doses

INTRODUCTION: The pharmacokinetics of PPI differs by the kind and this may lead the difference of therapeutic effect, especially symptom relief in early phase. Since genetic polymorphism of CYP2C19 is different in ethnic group and the standard dose of PPI in Japan differs from Western countries, efficacy of PPIs should be verified in each area. However, there is no study so far regarding early symptom relief by administrating standard dose of PPI in patient with reflux esophagitis (RE) in Japan. This prospective trial was performed to compare the efficacy of omeprazole and rabeprazole on early symptom relief in patients with RE. AIMS & METHODS: The patients who had been endoscopically diagnosed with RE within the past 12 months and who had moderate to severe reflux symptom of heartburn or gastric acid regurgitation. The severity was defined as score 4 and above in patient's reported symptom questionnaire with Global Overall Symptom (GOS) scale which have a seven point Likert scale. Subjects were randomized to either omeprazole 20mg od(O) or rabeprazole 10 mg od (R) for four weeks. The primary endpoint was to compare sustained